2ONE Labs Prevails in Trademark Dispute against IMB Zone Brand

Business by 2FIRSTS.ai

Dec.24.2024

US nicotine pouch brand 2ONE Labs wins preliminary injunction in trademark dispute with Imperial Tobacco's Zone brand.

On December 23rd, the American nicotine pouch brand 2ONE Labs announced on its official website that the brand, in partnership with distributor Performance Plus Marketing, had achieved a favorable preliminary injunction (PI) ruling in a trademark dispute with the Imperial Tobacco brand Zone. According to a court order dated December 20th, 2024, Zone's nicotine pouches are prohibited from being shipped to trade partners in the United States.

The CEO of 2ONE Labs, Vincent Schuman, stated that

This ruling is significant as it prohibits Imperial Tobacco from continuing to sell Zone nicotine pouches in the United States until the ongoing 2ONE trademark lawsuit is resolved.

According to the judge's ruling, the defendant (Imperial) is prohibited from selling oral nicotine products with the Bullseye trademark or any similar symbol. (Case number: CV 24-08124-MWF(Ex) Title: 2ONE Labs Inc. et al v. ITG Brands, LLC et al)

We are pleased that the court has made the correct decision to approve this PI. This is an extraordinary remedy for 2ONE and sets the foundation for their victory in the trademark infringement lawsuit against Imperial Tobacco.

References:

[1] 2ONE Labs, Inc. Secures Federal Preliminary Injunction Against ITG Brands and Affiliates in Trademark Infringement Case

Also Read:

[1] 2ONE Labs Announces PMTA Submission Update, Nicotine Pouch Products Receive FDA 'Acceptance' Again

[2] U.S. nicotine pouch brand 2ONE Labs says 2ONE® gains FDA “approval”

[3] Lawsuit Filed Against Imperial Brands Over Trademark Infringement

#North America #United States #Legislation #Nicotine pouches

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Altria Q3 2025 Earnings Report: Net Revenue of $6.072 Billion and Launch of on!PLUS in the U.S.

Altria reported Q3 2025 net revenue of $6.072 billion, a 3.0% year-on-year decline. Adjusted EPS increased 3.6% to $1.45. The company expanded its share repurchase program to $2 billion and launched the on!PLUS nicotine pouch in Florida, North Carolina, and Texas.

Oct.31 by 2FIRSTS.ai

Tobacco harm reduction advocates criticize COP11 for limiting public participation and call for inclusion of harm reduction products in discussions

The Conference of the Parties to the World Health Organization's Framework Convention on Tobacco Control (COP11) will convene in Geneva in November to discuss global tobacco control policies. Tobacco harm reduction advocates worry that the meeting may only avoid further policy damage without achieving substantive progress. They point out that COP11 limits public participation and call for strengthened discussion on safe nicotine products.

Sep.30 by 2FIRSTS.ai

British Museum Ends Long-Running Sponsorship with Japan Tobacco International

According to The Guardian, the British Museum has ended its 15-year sponsorship with Japan Tobacco International after government inquiries into whether the deal breached WHO tobacco-control rules. Critics had long opposed the partnership, while the museum said sponsorship remains essential for its financial stability and public access.

Nov.20

PMI Japan to Launch Limited Edition IQOS ILUMA i "Galaxy Blue", Introduces New TEREA Clear Regular Flavo

PMI Japan unveils limited edition IQOS ILUMA i in Galaxy Blue, inspired by the universe, set to launch on October 29.